New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
06:06 EDTIMUCImmunoCellular allows IND for ICT-140
ImmunoCellular Therapeutics announced that the FDA has allowed the investigational new drug, or IND, application for ICT-140, paving the way for conducting a clinical trial. ICT-140 is a dendritic cell vaccine targeting seven antigens that are over-expressed in ovarian cancer, as well as cancer stem cells. ImmunoCellular filed the IND application with the FDA in the Q4 of FY12, as planned.
News For IMUC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 24, 2014
06:05 EDTIMUCImmunoCellular established licensing agreement with Caltech
Subscribe for More Information
September 17, 2014
06:05 EDTIMUCImmunoCellular receives positive regulatory feedback on ICT-107
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use